Everything below concerns drug affinity complex. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-16. Numbers and descriptions here follow the published literature rather than marketing material.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | Reverse-phase HPLC | Reported as area percentage |
| Identity confirmation | Mass spectrometry | Electrospray or laser desorption |
| Powder storage | Minus 20 degrees Celsius or lower | Dark and dry conditions |
| Solution storage | Two to eight degrees Celsius | Avoid repeated freeze-thaw |
| Appearance | White to off-white powder | Common lyophilized form |
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
== Importance == Two pathways appear to exist in L. plantarum for transforming pyruvate into D-lactate. One of them involves the NAD-dependent lactate dehydrogenase that directly produces D-lactate (LdhD), and the other is through the sequential activities of an L-specific lactate dehydrogenase followed by lactate racemase. If the LdhD enzyme is inactivated or inhibited, lactate racemase provides the bacterium with a rescue pathway for the production of D-lactate. This pathway is significant because the production of D-lactate in L. plantarum is linked to the biosynthesis of the cell wall. Mutants lacking LdhD activity that also had the lar operon deleted only produced L-lactate, and peptidoglycan biosynthesis was not able to occur.
== Additional future research == Positive psychology research and practice is currently conducted and developed in various countries throughout the world. To illustrate, in Canada, Charles Hackney of Briercrest College applies positive psychology to the topic of personal growth through martial arts training; Paul Wong, president of the International Network on Personal Meaning, is developing an existential approach to positive psychology, which is framed in the second wave positive psychology (PP 2.0). The research program 'Understanding Positive Emotions' at Human Science Lab, London, investigates how material well-being and perceptual well-being work as relative determinants in conditioning our mind for positive emotions. Cognitive and behavioral change, although sometimes slight and complex, can produce an 'intense affect'. Isen (2009) remarked that further progress requires suitable research methods, and appropriate theories on which to base contemporary research. Chang (2008) suggested that researchers have a number of paths to pursue regarding the enhancement of emotional intelligence, even though emotional intelligence does not guarantee the development of positive affect; in short, more study is required to track the gradient of positive affect in psychology.
== Education == After graduating from National Taiwan University, Chen completed doctoral studies in the United States and earned his Ph.D. in physical chemistry from Iowa State University in 1997 under professor Cheuk-yiu Ng. She then completed post-doctoral research at Ames Laboratory in 1997, and then at Yuan-Pern Lee's group at National Tsing Hua University in 1999.
Sources: en.wikipedia.org
=== Health === In a February 2026 livestream, part of an interview with The New York Times, Peters listed substances that were part of his daily routine, including testosterone, Accutane, retatrutide, and nebivolol. He began taking testosterone shots at 14. He also told The New York Times that he suspects he is sterile after years of injecting himself with testosterone and alluded to not necessarily enjoying the act of sex. Declaring himself infertile in the past due to testosterone injections, Peters explained: "So it's just like a negative feedback loop when you're not needing to produce testosterone anymore because your body realizes, okay, we're getting it from an outside source." Peters has stated that he is on the autism spectrum, although he has not been professionally diagnosed. He shared in a June 29, 2026, tweet that he used to stalk strangers so he could study neurotypical human behavior:
The acidity of lactic acid impedes biological processes. This can be beneficial to the fermenting organism as it drives out competitors that are unadapted to the acidity. As a result, the food will have a longer shelf life (one reason foods are purposely fermented in the first place); however, beyond a certain point, the acidity starts affecting the organism that produces it. The high concentration of lactic acid (the final product of fermentation) drives the equilibrium backwards (Le Chatelier's principle), decreasing the rate at which fermentation can occur and slowing down growth. Ethanol, into which lactic acid can be easily converted, is volatile and will readily escape, allowing the reaction to proceed easily. CO2 is also produced, but it is only weakly acidic and even more volatile than ethanol. Acetic acid (another conversion product) is acidic and not as volatile as ethanol; however, in the presence of limited oxygen, its creation from lactic acid releases additional energy. It is a lighter molecule than lactic acid, forming fewer hydrogen bonds with its surroundings (due to having fewer groups that can form such bonds), thus is more volatile and will also allow the reaction to proceed more quickly. If propionic acid, butyric acid, and longer monocarboxylic acids are produced, the amount of acidity produced per glucose consumed will decrease, as with ethanol, allowing faster growth.
=== Special populations === It is recommended that women with active tuberculosis who are pregnant or breastfeeding take isoniazid. Preventive therapy should be delayed until after giving birth. Nursing mothers excrete a relatively low and non-toxic concentration of INH in breast milk, and their babies are at low risk for side effects. Both pregnant women and infants being breastfed by mothers taking INH should take vitamin B6 in its pyridoxine form to minimize the risk of peripheral nerve damage. Vitamin B6 is used to prevent isoniazid-induced B6 deficiency and neuropathy in people with a risk factor, such as pregnancy, lactation, HIV infection, alcoholism, diabetes, kidney failure, or malnutrition. People with liver dysfunction are at a higher risk for hepatitis caused by INH, and may need a lower dose. Levels of liver enzymes in the bloodstream should be frequently checked in daily alcohol drinkers, pregnant women, IV drug users, people over 35, and those who have chronic liver disease, severe kidney dysfunction, peripheral neuropathy, or HIV infection since they are more likely to develop hepatitis from INH.
=== Dark skin as deficiency risk === Melanin, specifically the sub-type eumelanin, is a biomolecule consisting of linked molecules of oxidized amino acid tyrosine. It is produced by cells called melanocytes in a process called melanogenesis. In the skin, melanin is located in the bottom layer (the stratum basale) of the skin's epidermis. Melanin can be permanently incorporated into the skin, resulting in dark skin, or else have its synthesis initiated by exposure to UV radiation, causing the skin to darken as a temporary sun tan. Eumelanin is an effective absorbent of light; the pigment can dissipate over 99.9% of absorbed UV radiation. Because of this property, eumelanin is thought to protect skin cells from sunlight's ultraviolet A (UVA) and ultraviolet B (UVB) radiation damage, reducing the risk of skin tissue folate depletion, preventing premature skin aging and reducing the risks of sunburn and skin cancer. Melanin inhibits UVB-powered vitamin D synthesis in the skin. In areas of the world not distant from the equator, abundant, year-round exposure to sunlight means that even dark-skinned populations have adequate skin synthesis. However, when dark-skinned people cover much of their bodies with clothing for cultural or climate reasons, or are living a primarily indoor life in urban conditions, or live at higher latitudes which provide less sunlight in winter, they are at risk for vitamin D deficiency. Vitamin D deficiency is particularly common among people with a dark complexion.
Sources: en.wikipedia.org
=== Obesity === GLP-1 agonists are recommended as an add-on therapy to lifestyle intervention (calorie restriction and exercise) in people with a BMI ≥ 30 kg/m2 or with a BMI ≥ 27 kg/m2 with at least one weight-related comorbidity, which can include high blood pressure or high cholesterol. Some GLP-1 agonists are more effective than other weight-loss drugs, but bariatric surgery is still considered the most effective and sustainable way to lose weight. Genetics is believed to play a role in both GLP-1 weight loss efficacy and side effects. GLP-1 agonists' weight-reducing effects come from a combination of peripheral effects and activity in the central nervous system. In the brain, GLP-1 agonists reduce weight by crossing the blood–brain barrier, via passive diffusion or receptor mediated transcytosis, and directly activating the satiety hormones in the hypothalamus. Three GLP-1 auto-injector medications are approved specifically for weight management: semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda). In randomized controlled trials, people lose on average 5–20% of their initial body weight depending on the substance and the dose. Studies reported that on average people regain more than half (50–70%) of the lost weight within a year after stopping any of these medications. People return to their previous weight within a year and a half after stopping these medications. Studies show that there is no improvement in quality of life despite the weight loss.
== Side effects == As with other opioids, tolerance and physical and psychological dependence develop with repeated dihydrocodeine use. All opioids can impair the mental or physical abilities required for the performance of potentially hazardous tasks such as driving or operating machinery if taken in large doses. Itching and flushing and other effects of blood vessel dilation are also common side-effects, due to histamine release in response to the drug using one or more types of receptors in the CNS or other responses elsewhere in the body. First-generation antihistamines such as tripelennamine (Pyrabenzamine), clemastine (Tavist), hydroxyzine (Atarax), diphenhydramine (Benadryl), cyproheptadine (Periactin), brompheniramine (Dimetapp), chlorphenamine (Chlor-Trimeton), doxylamine (NyQuil) and phenyltoloxamine (Percogesic Original Formula) not only combat the histamine-driven side-effects, but are analgesic-sparing (potentiating) in various degrees. The antihistamine promethazine (Phenergan) may also have a positive effect on hepatic metabolism of dihydrocodeine as it does with codeine. Higher doses of promethazine may interfere with most other opioids with the exception of the pethidine family (Demerol and the like) by this or other unknown mechanisms. As with all drugs, side-effects depend on the person taking the medication. They can range in severity from mild to extreme, from headaches to difficulty breathing. Constipation is the one side-effect of dihydrocodeine and almost all opioids which is near-universal.
Biden did not support national same-sex marriage rights while in the Senate and voted for the Defense of Marriage Act, but opposed proposals for constitutional amendments that would have banned same-sex marriage nationwide. Biden has supported same-sex marriage since 2012. As a senator, Biden forged deep relationships with police groups and was a chief proponent of a Law Enforcement Officers' Bill of Rights measure that police unions supported but police chiefs opposed. In 2020, Biden also ran on decriminalizing cannabis, after advocating harsher penalties for drug use as a senator. Biden believes action must be taken on climate change. As a senator, he co-sponsored the Boxer–Sanders Global Warming Pollution Reduction Act, the most stringent climate bill in the United States Senate. Biden supports nature conservation. According to a report from the Center for American Progress, he broke several records in this domain. He took steps to protect old-growth forests. Biden opposes drilling for oil in the Arctic National Wildlife Refuge. He wants to achieve a carbon-free power sector in the U.S. by 2035 and stop emissions completely by 2050. His program included reentering the Paris Agreement, green building and more. Biden supports environmental justice, including climate justice and ocean justice. Biden called global temperature rise above the 1.5°C limit the "only existential threat humanity faces even more frightening than a nuclear war".
Sources: en.wikipedia.org
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.
Reverse-phase high-performance liquid chromatography is used for purity. Mass spectrometry confirms molecular weight and sequence integrity. Amino acid analysis offers an additional compositional check.
Published stability data for dissolved material are limited and vary with conditions. Refrigerated solutions are generally used within a short period. The exact shelf life depends on concentration, buffer, and handling.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.